실시간
FierceBiotechCancer-focused Parabilis’ upsized $670M IPO breaks new for record for biotechsFierceBiotechSanofi halts phase 3 autoimmune trial early over insufficient efficacy as pipeline woes continueLabiotechBeyond amyloid and dopamine: emerging technologies reshaping neurologyEndpoints NewsParabilis' $670M IPO sets new biotech record, will fund cancer drugeLifeAltered cognitive processes shape tactile perception in autismeLifeCell size modulates ferroptosis susceptibilityClinical OMICsExposure to Moderate Air Pollution Raises Cardiovascular Disease RiskEndpoints NewsEli Lilly's claims data deadline may kick off new 340B fightClinical OMICsFirst Phase III for Resected CRC ctDNA-Guided Therapy Shows Mixed ResultsAgilentAgilent Showcases Integrated Mass Spectrometry and Chromatography Solutions at ASMS 2026 - the-scientist.comEndpoints NewsGrace Science says FDA bottleneck jeopardizes rare disease therapyClinical OMICsDigital Pathology and the NHS: Overcoming Barriers to a More Connected Future
Illumina 2026년 4월 26일

Did DRAGEN v4.5’s AI Genomics Push Just Shift Illumina’s (ILMN) Investment Narrative? - simplywall.st

Did DRAGEN v4.5’s AI Genomics Push Just Shift Illumina’s (ILMN) Investment Narrative? - simplywall.st

원문
본문을 이용할 수 없습니다. 원본 출처를 확인하세요.